Practical Defense Strategies for Combating Generics CompetitionDecision ResourcesJune 21, 2007 23 Pages - SKU: DECR1507361 |
|
Out-of-Pocket Healthcare 2012
4/3/2012 | published by: Kalorama Information
Despite numerous attempts to reign in costs of healthcare, consumers are increasingly paying for healthcare products and services from their own monies. The costs of health care products and services continue
|
more...
|
$995.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
4/30/2012 | published by: GBI Research
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion Summary GBI Research, the leading business intelligence provider, has released its latest research, “Cytotoxic Therapies Market
|
more...
|
$3,500.00
|
|
Oman Pharmaceuticals and Healthcare Report Q2 2012
3/6/2012 | published by: Business Monitor International
BMI View: Oman’s 2012 budget allocated a greater sum of money to the healthcare sector, in line with BMI’s view that the Arab spring would lead to greater spending in this segment. The Omani government
|
more...
|
$1,175.00
|
|
Zimbabwe Pharmaceuticals and Healthcare Report Q2 2012
3/6/2012 | published by: Business Monitor International
BMI View: On account of its unpredictable and unfavourable operating environment and limited funding for and investment in healthcare and medicines, Zimbabwe’s pharmaceutical market will remain unattractive to foreign companies for the foreseeable future. Poor
|
more...
|
$1,175.00
|
|
Peru Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: Peru’s large and growing population underpins the potential of its pharmaceutical market,especially given the rising prevalence of non-communicable diseases. However, Peru remains listed onthe US Trade Representative (USTR)’s Special 301 Report Watch List,
|
more...
|
$1,175.00
|
|
Research Report on Chinese Bio-pharmaceutical Industry, 2012
3/21/2012 | published by: China Research and Intelligence Co., Ltd.
In China, biological products consist of vaccines, blood products, cytokine, diagnostic reagents and other active agents (including toxins, antigens, allergen, and recombinant DNA products, etc.). In China, animal vaccine belongs to veterinary medicine rather than
|
more...
|
$3,000.00
|
|
Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
3/23/2012 | published by: GBI Research
Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion Summary GBI Research, the leading business intelligence provider, has released its latest research “Anti-Hypertensives Market to 2017 -
|
more...
|
$3,500.00
|
|
Switzerland Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: The expected growth of the Switzerland’s ageing population over the next 50 years will havean unprecedented impact on the demand for healthcare. The elderly require more medical check-ups andcare than young people as
|
more...
|
$1,175.00
|
|
Bangladesh Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: Although the growth of Bangladesh’s pharmaceutical market is expected to remain in doubledigits over the forecast period, some of the gains will be negated by high levels of inflation. Additionally,although economic development and
|
more...
|
$530.00
|
Related Markets
Biopharmaceuticals Reports
- Research Report on Chinese Bio-pharmaceutical Industry, 2012
- Regulatory Intelligence on Biologics Recalls – Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes
- Biologics Market in Brazil
- Global Biosimilars Market Forecast to 2015
- Biosimilars: Current Situation & Future Prospects, Worldwide
